regulatory
confidence high
sentiment positive
materiality 0.75
SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader
BeyondSpring Inc.
- Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.
- FDA cleared IND for ST-01156 (RBM39); first-in-human trial expected Q1 2026.
- SEED has received ~$60M in equity and payments from Eli Lilly and Eisai partnerships.
- BeyondSpring expects to continue consolidating SEED as it retains substantive control.